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A B S T R A C T
Adrenoleukodystrophy is a neurometabolic disorder caused by a defective peroxisomal ABCD1 transporter of
very long-chain fatty acids (VLCFAs). Its pathogenesis is incompletely understood. Here we characterize a ne-
matode model of X-ALD with loss of the pmp-4 gene, the worm orthologue of ABCD1. These mutants recapitulate
the hallmarks of X-ALD: i) VLCFAs accumulation and impaired mitochondrial redox homeostasis and ii) axonal
damage coupled to locomotor dysfunction. Furthermore, we identify a novel role for PMP-4 in modulating lipid
droplet dynamics. Importantly, we show that the mitochondria targeted antioxidant MitoQ normalizes lipid
droplets size, and prevents axonal degeneration and locomotor disability, highlighting its therapeutic potential.
Moreover, PMP-4 acting solely in the hypodermis rescues axonal and locomotion abnormalities, suggesting a
myelin-like role for the hypodermis in providing essential peroxisomal functions for the nematode nervous
system.
1. Introduction
Peroxisomes are single membrane-bound ubiquitous organelles that
play key roles in redox homeostasis and the metabolism of lipids, in
particular fatty acid β-oxidation, ether phospholipids, and bile acids
[1]. Impairments in any of these essential pathways are associated with
major clinical signs and symptoms, usually involving the nervous
system [2]. X-linked adrenoleukodystrophy (X-ALD, McKusick no.
300100) is the most common peroxisomal disease and leukodystrophy
with an incidence of 1:14700 births [3]. X-ALD is caused by a loss of
function of the ABCD1 gene, which encodes a peroxisomal transporter
that imports very long-chain fatty acids (VLCFAs) to be β-oxidized [4].
As a consequence, VLCFAs, especially hexacosanoic acid or C26:0, ac-
cumulate in tissues and plasma and constitute a pathognomonic bio-
marker for diagnosis. X-ALD is a complex inherited syndrome in which
the same mutation in the ABCD1 gene can lead to highly divergent
clinical phenotypes, such as childhood cerebral adrenoleukodystrophy
(cALD), chronic progressive adult-onset adrenomyeloneuropathy
(AMN) or cerebral AMN (cAMN) [5,6]. Therapeutic options are scarce,
and when diagnosed early, the cerebral forms of the disease (cALD and
cAMN) are only adequately treatable with an allogeneic bone marrow
transplant [7,8] or recently, with haematopoietic stem cell gene
therapy for cALD [9,10]. However, no pharmacological treatment has
been shown to be beneficial for either form of the disease [11],
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although several repurposed drugs have been proposed [12–15].
The two mouse models of X-ALD (Abcd1- and Abcd1-/Abcd2−/−
mice) develop late-onset axonopathy, with signs and symptoms re-
sembling AMN visible at 20 and 12 months of age, respectively [16,17].
Using these mouse models and patient samples, several studies have
indicated that VLCFA-induced oxidative stress is a critical, early pa-
thogenic factor in X-ALD [18–20], although the exact mechanisms by
which redox imbalance causes neurodegeneration in X-ALD are in-
completely understood.
Here, we established a cost-effective disease model with the aim of
identifying critical steps leading to axonal demise and establishing a
rapid and amenable platform for high-throughput drug screening in the
nematode Caenorhabditis elegans. pmp-4 is the worm orthologue of
ABCD1, and its function has thus far been unexplored. Despite the fact
that the C. elegans nervous system is not myelinated [21], thus pre-
cluding the study of the physiopathology of the infantile form of X-ALD
(cALD), this work indicates that pmp-4(ok396) worms may constitute a
valuable model of the axonopathy occurring in the adult form of the
disease, AMN. This study sheds light on the mechanisms leading to
mitochondrial and lipid droplet (LD) metabolism impairment while
highlighting the prominent role of the hypodermis in axonal main-
tenance in the nematode.
2. Material and methods
A more detailed explanation of the methodology, strains, and




dioxo-1,4 cyclohexadienyl) decyltriphenyl-phosphonium methane-
sulfonate) was provided by MP Murphy. CoQ10, paraquat (PQT), 2,4-
Dinitrophenylhydrazine, thenoyltrifluoroacetone (TTFA), antimycin,
sodium azide and dimethylsulfoxide (DMSO) were purchased from
Sigma-Aldrich. H2DCFDA and MitoSOX Red were obtained from Life
Technologies.
2.2. Strains
Worm strains were maintained under standard conditions on
Escherichia coli OP50 at 20 °C. All the strains used were provided by the
Caenorhabditis Genetic Center (CGC) unless otherwise indicated. N2
(Bristol) was used as the WT strain (N2). The partial deletion strain
RB675, pmp-4(ok396), was backcrossed 10 times into the N2 strain
prior to experimental work.
All the strains mentioned in the manuscript are detailed in
Supplementary Table S1. Plasmid HYM772 (for targeting peroxisomes
in hypodermis) was kindly provided by Dr. Ho Yi Mak (Stowers In-
stitute for Medical Research, Kansas City, MO, USA).
2.3. In silico sequence analysis
The alignment of protein sequences between the indicated species
was performed by ClustalW software, version 2 [22]. The Pex19
binding site was predicted by using the PTS predictor tool in the per-
oxisome database: www.peroxisomedb.org.
2.4. Plasmids and nematode transgenesis
The vectors pPD95.79, pPD95.77 and pPD96.32 (Addgene,
Teddington, UK) were used as backbones for all the plasmids generated
in this study. The constructs are listed in Supplementary Table S2, and
detailed cloning information will be provided upon request. Transgenic
strains were generated using standard microinjection techniques [23]
and are listed in Table S1. Plasmids were injected into worm adult
gonads alone or together with the plasmid pRF4 (100 ng/μl), which
encodes a mutant collagen [rol-6(su1006)] that induces a dominant
“roller” phenotype or the plasmid pCFJ90 (2.5 ng/μl), which expresses
mCherry under the control of the myo-2 promoter [Pmyo-2::mCher-
ry::unc-54utr], as co-injection markers depending on the experiments.
In all cases, at least 3 independent transgenic lines were generated and
analysed, all showing similar results.
2.5. Generation of the PMP-4 antibody
A PMP-4 antibody was obtained following the standard procedures
at the IGBMC core facilities, Strasbourg, France. The PMP-4 peptide
CQLLGGNEDHLNMTIDTDDSE (see Supplementary Fig. S1A) was cou-
pled with maleimide-activated ovalbumin (Thermo Scientific, Madrid,
Spain) and injected into rabbits. The polyclonal anti-PMP-4 antibody
was purified from rabbit serum through a gel matrix (Sulfolink * cou-
pling gel). Fractions of 1 ml were eluted from the column, tested for
activity by immunoblotting, aliquoted and stored at -20 °C until use.
2.6. Analysis of PMP-4 expression by western blotting
PMP-4 expression was performed in synchronized populations of
worms obtained by bleaching. To collect L1 worms, eggs were allowed
to hatch on Nematode growth medium (NGM)-seeded plates and col-
lected after 4–6 h of feeding at 20 °C. To isolate the other larval stages,
the eggs were allowed to hatch on M9 O/N at 20 °C, and the resulting
synchronized L1 worms were added to NGM-seeded plates; the animals
were harvested at the appropriate developmental stage after 10 h (for
L2 animals), 24 h (for L3 animals), 48 h (for L4 animals), and 7 days
(for post-reproductive adult animals). The worms were washed ex-
tensively with M9 to remove bacteria, and the worm pellets were frozen
at -80 °C.
The Western blot analysis was performed as described [15]. Eight
micrograms of protein was separated by 8% SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) and blotted onto nitrocellulose membranes
(Bio-Rad, Barcelona, Spain). The membranes were then incubated with
anti-PMP-4 (1:500 rabbit polyclonal) and anti-rabbit secondary anti-
bodies (1:5000. DAKO, Barcelona, Spain), and the proteins were vi-
sualized with an ECL plus detection reagent (GE Healthcare, Barcelona,
Spain). The same process was performed for the detection of DNP-de-
rived oxidative damage with slight modifications specific for the de-
tection of oxidized proteins and detailed below in the oxidative stress
section. Densitometric analysis was performed using ImageJ software.
2.7. Immunocytochemistry
Whole-mount immunofluorescent staining for PMP-4 and/or GFP
was performed as described [24]. The samples were probed with pri-
mary antibodies against PMP-4 described in the previous section at a
1:100 dilution and/or anti-GFP (Abcam, Cambridge, UK) at a 1:200
dilution. Secondary antibodies conjugated to Alexa Fluor 555 (PMP-4)
dye and/or Alexa Fluor 555 (GFP) (Molecular Probes, Barcelona, Spain)
were used at a 1:1000 dilution. Images were acquired on a Leica Con-
focal SP5 microscope. Nuclei were detected by DAPI counterstaining.
2.8. Imaging
Protein blot images were acquired using the Fujifilm Image Reader
(NIH, ver. 1.43). The quantification of protein levels was performed
using Multigage software v3.0 (Fujifilm).
Fluorescent microscopy was performed using a Nikon Eclipse E800
epifluorescence microscope equipped with an Endow GFP HYQ filter
cube (Chroma Technology). Confocal microscopy was performed using
a Leica TCS-SP5 confocal spectral microscope (Barcelona, Spain) and
analysed by ImageJ software (NIH, ver. 1.43). Video recordings of the
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thrashing behaviour were performed on a stereomicroscope (SteREO
Lumar. V12, Carl Zeiss, Madrid, Spain) coupled to a digital camera
(Jenoptik, model ProgRes CF scan).
2.9. Lipid extraction and fatty acid quantification
Newly hatched L1 larvae were grown on regular NGM plus OP50 for
48 h at 20 °C. L4 staged animals were washed and collected from 10
plates of 10 cm in diameter and cleaned from bacteria with M9 buffer.
Subsequently, the worms were washed twice with S Basal buffer and
finally with Optimal LC/MS H2O. The worms were settled by gravity on
ice, and the water was carefully removed. The worm pellets were
quickly frozen in liquid nitrogen and stored frozen at -80 °C until
analysis.
For homogenization, the frozen cell pellets were briefly thawed, and
0.5 ml MilliQ water was added, mixed by vortexing and transferred to a
“ball sonicator tube”. The original tube was rinsed with 0.5 ml MilliQ
water, and the rinse was also transferred to the “ball sonicator tube”. A
small steel ball was added, and the tube was capped. The tubes were
mixed in the cold for 2–3 min 25 times per 1 s in the Qiagen TissueLyser
II. The samples appeared to be well mixed and broken into fine parti-
cles. Five-microliter aliquots were removed for total protein, 10-μl ali-
quots were removed for LC/MS/MS, and 0.5 ml x 2 aliquots were re-
moved for total lipid extract by the Folch method [25]. The Lyso-PC
FIA-MS/MS analysis was performed as previously shown [26] (WT,
n = 12 and pmp-4(ok396), n = 10). The daf-22(ok693) strain accu-
mulates VLCFA [27] and was therefore used as a positive control
(n = 6). The results are expressed as pmol/mg protein.
2.10. Thrashing assay
Thrashing is a rhythmic pattern of activity where the worm oscil-
lates side-to-side around its midpoint. A single thrash was defined by a
movement through the midpoint and back. The thrashing assay was
performed blindly and in liquid medium as described previously [28]. A
drop of 2% agarose was poured over the glass slide and allowed to dry.
After adding 20 μl of M9, L4 or L4+7 synchronized animals, the worms
were placed on the drop and left for 2 min. Thrashes were counted for
30 s, and every animal was counted three consecutive times to obtain
an average. This value was multiplied by two to obtain an estimate per
minute. A single thrash was defined as a complete change in the di-
rection of the body down the midline. Animals who were motionless for
10 s were discarded from the analysis.
2.11. Quantification of GABAergic-associated abnormalities using the
juIs76 [Punc-25::gfp] reporter strain
Worms were grown at 20 °C for at least two generations before the
experiments. Animal age refers to the adult age measured in days,
calculated by adding one day consecutively from the given animal went
through L4 [29]. The animals were transferred daily to avoid mixing
populations, and the animals were considered dead when they stopped
pharyngeal pumping and failed to respond to mild touch by a platinum
wire picker. After synchronization, F1 hermaphrodite animals were
maintained at 20 °C until the late L4 larval stage and then transferred to
the final assay plates (50 worms/plate) supplemented or not with the
indicated concentration of drugs (PQT 0.2 mM, CoQ 1 mg/ml and
MitoQ, 5 μg/ml) when required.
On the actual day of the experiment, worms of the appropriate age
and genotype, with or without drugs, were washed, anaesthetized in
10 mM sodium azide on 6% agar pads and subsequently mounted for
image analysis. The worms were scored for the number of GABAergic
neurons, gaps in the ventral cord, gaps in the dorsal cord and defects in
axonal morphology [30].
The applied formula used to quantify axonal damage is: % of axonal
damage = [((number of commissural abnormalities + number of gaps/
animal))/number of axons detected) x100].
The experiment was performed blindly and by different in-
vestigators to guarantee the reliability of the obtained measurements.
2.12. Fasting experiments
L4 animals were starved for 24 h under standard conditions at 20 °C.
2.13. Analysis of lipid droplets
Fat accumulation was analysed by fixative and non-fixative live
methodology. The animals were washed with M9 buffer and fixed with
2% paraformaldehyde. The worms were then subjected to three freeze-
thaw cycles to disrupt the cuticles and incubated for 5 min and 10 min
on ice. After 3 washes with cold M9, worms were dehydrated through
an ethanol series (25%, 50%, 70%) and 2–5 volumes of 3% Sudan Black
B solution (Sigma-Aldrich, Madrid, Spain) were added to the worms,
which were then incubated overnight. The worms were rehydrated
through an ethanol series (70%, 50%, 25%) and finally with M9. Lipid
droplets were detectable as large black granules under a bright-field
microscope.
The non-fixative live methodology was performed by using the
strain VS20 (hjIs67 [Patgl-1::atgl-1::gfp]), in which ATGL-1 localizes to
the surface of the lipid droplets [31]. This strain was crossed with pmp-
4(ok396) animals (pmp-4(ok396); hjIs67 [Patgl-1::atgl-1::gfp]), and the
resulting progeny were analysed by confocal microscopy in parallel
with the corresponding age-matched controls.
2.14. Oxidative stress assays
The sensitivity to oxidative stress was analysed systematically by
using different approaches.
Protein carbonylation: Synchronized L4 animals grown at 20 °C
were used. Fifteen micrograms of worm proteins were run on an 8%
SDS gel, transferred to nitrocellulose and incubated with a solution of
0.2% 2,4-Dinitrophenylhydrazine (DNPH, Sigma-Aldrich, Madrid,
Spain). This method is based on the formation of a hydrazone (DNP)
resulting from the reaction of protein-bound carbonyl and 2,4-DNPH
[20]. An antibody against DNP was used to detect carbonylated protein.
Carbonylated proteins were finally detected with ECL western blotting
analysis systems described previously for PMP-4 Western blot detec-
tion.
Measurement of intracellular ROS was performed as previously
described [32,33]. The amount of ROS was detected with the mem-
brane-permeable non-fluorescent dye 2,7-dichlorodihydrofluorescein-
diacetate (H2DCFDA), which can enter the cell where it is converted to
a polar non-fluorescent derivative (dichlorofluorescein diacetate,
H2DCFDA). Then, H2DCFDA is rapidly oxidized to the highly fluor-
escent 2′,7′-dichlorofluorescein in the presence of intracellular ROS. To
detect changes in the levels of ROS, a stock solution of 10 mM carboxy-
H2DCFDA (Molecular Probes, Barcelona, Spain) in DMSO was diluted to
10 μM in M9 buffer. Young adult worms were transferred into the
staining solution and stained for 30 min at 20 °C. The worms were
mounted on a thick layer of half-dried agar pad on microscopic glass
slides and then subjected to fluorescence microscopy (see above).
Measurement of mitochondrial ROS with MitoSOx probes was per-
formed as previously described [34]. MitoSOX Red (Life Technologies,
Madrid, Spain) was diluted in DMSO at 10 mM and frozen at -20 °C as
stock. Before staining, the stocks were diluted in M9 buffer at a 1:1000
dilution. L4-staged worms were transferred into the staining solution
and stained overnight at 20 °C in a mixer. After incubation, the worms
were washed twice with M9 buffer and mounted on a 6% layer of half-
dried agar pad on microscopic glass slides and then subjected to
fluorescence microscopy. Pictures were taken by NIS software, and the
fluorescence was analysed by ImageJ software.
Sensitivity to mitochondrial inhibitors: L4 synchronized animals
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were incubated separately with PQT (4 mM) [35], thenoyltri-
fluoroacetone (TTFA) (2 mM), 3-nitropropionic acid (3-NP) (100 mM),
antimycin (1.27 mM) or sodium azide (1 mM) [36]. The worms were




CoQ nematode treatment was performed as previously described
[30]. CoQ10 (100 mg) was dissolved in 10 ml of distilled water con-
taining 0.06% Tween-80. Ten millilitres of this stock was added to NG
agar medium (total 100 ml) after autoclaving and cooling to 60 °C. For
PQT and CoQ10 combined plates, paraquat was supplemented at a final
concentration of 2 mM in NGM agar containing 1 mg/ml CoQ10
(1.158 mM). The lethality test was performed as described above.
2.15.2. MitoQ assay
MitoQ nematode treatment was performed as previously described
[37,38]. One milligram of MitoQ was dissolved in 1 ml of distilled
water, and 250 μl of this stock was added to 60 °C NG agar medium
(total 50 ml) autoclaving and cooling to 60 °C. We confirmed that C.
elegans survival is not affected by TPP+ and MitoQ at this concentra-
tion. For PQT and MitoQ10 combined plates, PQT was supplemented at
a final concentration of 4 mM in NGM agar containing 5 μg/ml MitoQ
(7.3 μM). The lethality test was performed as described previously.
2.15.3. Statistics
All data are presented as the mean ± SD. Group means were
compared with either Student's t-test, one-way or two-way ANOVA,
followed by Tukey's post hoc test. All P values were two-tailed, and a P
value of less than 0.05 was considered statistically significant. All sta-
tistical analyses were analysed using SPSS software.
3. Results
3.1. pmp-4 encodes the peroxisomal ABCD1 orthologue, and pmp-
4(ok396) loss of function mutants recapitulate the main hallmarks of X-ALD
Phylogenetic analysis identified pmp-4 as the orthologue and ancestor
of mammalian peroxisomal transporters ABCD1 and ABCD2 in C. elegans
[39]. PMP-4 shows 75% similarly to ABCD1 at the amino acid level, and
73% to ABCD2 (Supplementary Fig. S1A). In C. elegans, 5 orthologs of
mammalian ABCD transporters exist: 1 for ABCD1 and ABCD2 (pmp-4),
two for ABCD3 (pmp-1 and pmp-2) and two for ABCD4 (pmp-3 and pmp-5)
[39]. To identify the tissues in which pmp-4 is expressed, we used N2
worms harbouring the Ex001 [Ppmp-4::gfp] transcriptional reporter that
expresses GFP under the control of the pmp-4 promoter and found that
PMP-4 is mainly expressed in both the intestines and hypodermis
(Supplementary Fig. S1B), which are the main tissues for fat storage in C.
elegans [40]. Using an in silico mining tool for peroxisomal targeting se-
quences available at the peroxisome database (www.peroxisomedb.org)
[41], we predicted the presence of the PEX19 binding site, a PTS signal
for membrane proteins [42], between residues 140 to 151 of the PMP-4
coding sequence (Supplementary Fig. S1A), suggesting a peroxisomal
localization for this transporter in the nematode. To validate the in silico
prediction of the peroxisomal localization of PMP-4, we took advantage
of another peroxisomal targeting signal, PTS type-1 (PTS1), which has
been shown to target matrix proteins to peroxisomes in C. elegans [31].
Thus, using the strain hjIs37 [Pvha-6::rfp::PTS1], in which the peroxi-
somes are labelled with RFP in the intestine, we expressed PMP-4:GFP
under the control of its own promoter and found the colocalization
(yellow labelling) of both reporter proteins in the gut (Fig. 1A–D). Si-
milarly, using the strain Ex095 [Pdpy-7::gfp::PTS1] that labels peroxi-
somes with GFP in the hypodermis, we expressed PMP-4:mCherry under
the control of its own promoter and found colocalization in the
hypodermis (yellow labelling)(Fig. 1E–H). These results confirm the
presence of PMP-4 in peroxisomes in the two main peroxisomal-con-
taining tissues in C. elegans, the gut and the hypodermis [43].
To establish a model of X-ALD in the nematode, we used a strain
harbouring the pmp-4(ok396) allele, which contains an 867 bp deletion
encompassing exons 6 to 10 (www.wormbase.org) (Supplementary Fig.
S1C). pmp-4(ok396) worms did not show any obvious defects in growth
or maturation.
We generated a polyclonal antibody using the last 21 amino acids of
the C-terminal part of PMP-4 (Supplementary Fig. S1A) and performed
Western blot (WB) experiments that detected a band above 75 kDa in
wild-type (WT, N2 strain) homogenates. This molecular weight is ex-
pected for a protein of 734 amino acids, while no protein was observed
in pmp-4(ok396) extracts (Fig. 1I). As a positive control, we generated a
transgenic strain expressing the PMP-4 protein fused to GFP at the C-
terminus under the control of its own promoter in pmp-4(ok396) ani-
mals (pmp-4(ok396); Ex042 [Ppmp-4::pmp-4::gfp]) and used the homo-
genates for the WB (Fig. 1I). PMP-4 was not detected in pmp-4(ok396)
animals by immunofluorescence (Fig. 1J–K), demonstrating that pmp-
4(ok396) is a null allele. Furthermore, we observed that PMP-4 is well
expressed from the first larval stage (L1) to adulthood, with higher
expression from L3 onwards, whereas no expression was detected in
embryos (Supplementary Fig. S1D).
The main biochemical hallmark of X-ALD is the accumulation of
VLCFAs in complex lipids, especially in lysophosphatidylcholine (LPC)
[3,6,26], which is used as a robust diagnostic marker of X-ALD and,
recently, in newborn screening [3,26]. We performed a tandem mass
spectrometry analysis of LPC-VLCFAs from WT, pmp-4(ok396) and daf-
22(ok693) worms, the latter was used as a positive control for VLCFA
accumulation (Fig. 1L). daf-22(ok693) mutants lack the last enzyme of
the peroxisomal β-oxidation pathway called SCPx/thiolase and therefore
accumulate VLCFAs [27]. Here, we observed that LPC-C20:0, LPC-C22:0,
LPC-C24:0 and LPC-C26:0 were increased in both pmp-4(ok396) and daf-
22(ok693) worms (Fig. 1L), indicating a role for PMP-4 in importing
VLCFAs into peroxisomes for degradation, similar to its mammalian or-
thologue. The difference in levels of VLCFA between pmp-4(ok396) and
daf-22(ok693) mutants in C. elegans was not unexpected when compared
with human data. Indeed, C26:0 was 1.7-fold higher accumulated in
plasma from ACOX1 patients (the first rate-limiting enzyme of the per-
oxisomal β-oxidation) than in plasma from X-ALD patients [44]. In ad-
dition, de novo C26:0 synthesis was measured as the level of D3‐C26:0
produced from D3‐C22:0. Remarkably, D3‐C26:0 was increased in X-ALD
fibroblasts and the effect exacerbated in the peroxisomal β-oxidation
enzymes deficient fibroblasts (ACOX1-and HSD17B4-deficient fibro-
blasts) [45]. This difference of C26:0 levels between X-ALD patients and
patients with peroxisomal β-oxidation deficiency is probably due to
functional overlap between ABCD1 and ABCD2 peroxisomal transporters
as previously reported [16,39]. Elegant experiments in yeast showed that
the substrate specificities of HsABCD1, HsABCD2, and HsABCD3 are
overlapping even if they have distinctive preferences [46]. In C. elegans,
there are 5 distinct ABCD transporters which could also share redundant
functions that could explain the difference of VLCFA levels between pmp-
4(ok396) and daf-22(ok693) mutants [39].
We next investigated whether impaired redox homeostasis is a phe-
notypic trait of pmp-4(ok396) nematodes. Redox immunoblotting with
an antibody that recognizes dinitrophenol (DNP) modified protein car-
bonyls [20] showed that pmp-4(ok396) worms had significantly more
oxidatively damaged proteins than did WT nematodes (Fig. 1M). This
finding is correlated with higher levels of total reactive oxygen species
(ROS) measured with H2DCFDA probes [33] (Fig. 1N–O), in agreement
with evidence obtained in cellular, in vivo and ex vivo models of X-ALD
[47–49]. Of note, the daf-22(ok693) strain did not display increased ROS
production (Fig. 1N, P). We rescued the increased ROS production by
using a construct containing PMP-4:mCherry driven by the pmp-4 pro-
moter and injected into pmp-4(ok396) worms (pmp-4(ok396); Ex050
[Ppmp-4::pmp-4::mCherry]) (Fig. 1N–O, 1Q), in which H2DCFDA staining
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was normalized. To investigate whether the origin of ROS in the absence
of PMP-4 was mitochondrial, in a similar manner as in the fibroblasts of
X-ALD patients [50], we incubated the pmp-4(ok396) worms with the
MitoSOX probe, which specifically reacts with mitochondrial ROS [33].
The results indicated increased mitochondrial ROS in the mutant strain
(Fig. 1R–S). In contrast, daf-22(ok693) did not produce higher mi-
tochondrial ROS than WT (Fig. 1R, T), consistent with the data obtained
when using a probe labelling total ROS (Fig. 1P). The absence of redox
imbalance in daf-22(ok693) worms will be discussed later.
X-ALD is characterized by the axonal degeneration of corticospinal
tracts leading to spastic paraparesis in patients and locomotor disability
in mouse models, as evidenced by rotarod, treadmill and bar-cross tests
[16,17,51]. Here, we evaluated the motility of pmp-4(ok396) and WT
strains by a thrashing assay, in which nematodes were placed in liquid,
and the frequency of lateral swimming or thrashing movements was
estimated [28]. Thrashing assays were performed blindly at L4
(Supplementary Fig. S2A) and L4+7 days (Fig. 1U, movies S1-S2), well
after the worms reached adulthood. The pmp-4(ok396) mutants con-
sistently thrashed at a significantly reduced rate when compared to the
behaviour of WT at both ages tested in a comparable manner, thus
indicating a defect in motility (Fig. 1U, Supplementary Fig. S2A, movies
S1-S2). Finally, we examined axonal abnormalities by analysing the
structural integrity of GABAergic D-type motor neurons and their pro-
cesses in pmp-4(ok396) animals to evaluate whether locomotor phe-
notypes were associated with axonal degeneration, as noted in X-ALD
mouse models and patients [5,16,17]. To address this question, we used
the juIs76[Punc-25::gfp] strain with GFP-labelled GABAergic axons and
cell bodies of the ventral cord [52]. We found significant axonal da-
mage in pmp-4(ok396); juIs76 [Punc-25::gfp] worms compared to juIs76
[Punc-25::gfp] control animals, both before and after reaching adult-
hood, at L4 (Supplementary Figs. S2B–D) and L4+7 days, respectively
(Fig. 1V–W). Finally, we recovered axonal defects by injecting PMP-4
fused to mCherry into pmp-4(ok396) worms with GFP-labelled GA-
BAergic cells (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex065 [Ppmp-
4::pmp-4::mCherry]) (Fig. 1V–X).
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.freeradbiomed.2020.01.177
3.2. The loss of pmp-4 induces lipid droplet accumulation in the nematode
Lipid droplets (LDs) are dynamic organelles, such as peroxisomes,
that emerge from the endoplasmic reticulum membrane and serve as a
site for the storage of neutral lipids, such as triglycerides and choles-
terol [53–55]. Cells can form LDs in response to stress conditions, such
as inflammation or nutrient deprivation [56–58]. In C. elegans, the
majority of lipids are stored in LDs and are mainly located in gut and
hypodermal cells [59]. In other peroxisomal mutants, such as the dhs-
28(hj8) and daf-22(ok693) worms, which lack peroxisomal dehy-
drogenase and SCPx/thiolase, the third and fourth enzymes of the
peroxisomal β-oxidation pathway, respectively, an increase in LDs is
observed in the gut [31]. Thus, we hypothesized that LD formation
could also be altered in pmp-4(ok396)mutants. We studied the presence
of LDs using Sudan Black, a neutral lipid dye that stains LDs [60] and
found that the number of lipid granules with a diameter> 5 μm was
significantly increased in pmp-4(ok396) worms compared to WT ani-
mals (Fig. 2A and C). We next applied a 24 h fasting period to the
worms. This metabolic route was blunted in pmp-4(ok396) worms,
which could not use their lipid reservoirs when most needed
(Fig. 2A–D). Next, the increase in LDs visualized by Sudan black was no
longer detected by using a construct containing PMP-4:mCherry driven
by the pmp-4 promoter and injected into pmp-4(ok396) worms (pmp-
4(ok396); Ex050 [Ppmp-4::pmp-4::mCherry]) (Fig. 2A–E).
To complement these results with a specific marker of LDs, we chose
adipose triglyceride lipase 1 (ATGL-1), which is a coating component of
phospholipid monolayer delimiting LDs [61]. ATGL-1 fused to GFP
protein localizes at the surface of large LDs in dhs-28(hj8) peroxisomal
dehydrogenase mutant [31]. We crossed the strain hjIs67 [Patgl-1::atgl-
1::gfp] expressing ATGL-1:GFP [31] with the pmp-4(ok396) mutant and
the results showed the improved visualization of the enlarged LDs when
PMP-4 was absent (Fig. 2F-Q), similar to dhs-28(hj8) peroxisomal mu-
tants [31], corroborating the inability of the pmp-4(ok396) worms to
degrade LDs upon fasting (Fig. 2F-Q). In conclusion, pmp-4(ok396)
mutants recapitulate the increased size of LDs observed in peroxisomal
β-oxidation mutants, which is also refractory to fasting-induced lipo-
lysis.
3.3. Loss of PMP-4 increases vulnerability to mitochondrial ROS
To directly test the sensitivity of pmp-4(ok396) worms to mi-
tochondrial ROS, we incubated the animals with the pro-oxidant
paraquat (PQT), a redox cycler that stimulates superoxide production in
mitochondria at complex I [62]. Compared to WT animals, the pmp-
4(ok396) worms showed increased lethality under these conditions
(Fig. 3A). Furthermore, we tested the impact of classical inhibitors of
Fig. 1. C. elegans pmp-4(ok396) mutants recapitulate the main hallmarks observed in X-ALD. (A–D) The construct containing PMP-4:GFP under the control of
the pmp-4 promoter was injected into the strain labelling peroxisomes with RFP in the intestine (hjIs37 [Pvha-6p::rfp::PTS1]; Ex048 [Ppmp-4::pmp-4::gfp]). Images of
(A) RFP:PTS1 and (B) PMP-4:GFP staining. (C) Merge of images A and B. In yellow, colocalization of RFP:PTS-1 with PMP-4:GFP. (D) DIC-Nomarsky pictures
corresponding to the fluorescence images (n = 30). (E–H) The constructs containing GFP:PTS1 under the control of a specific hypodermal promoter (Pdpy-7) and
PMP-4:mCherry under the control of the pmp-4 promoter were coinjected in the N2 strain (Ex095 [Pdpy-7::gfp::PTS1 + Ppmp-4::pmp-4::mCherry]). Here, the per-
oxisomes are labelled with GFP in the hypodermis. Images of (E) GFP:PTS1 and (F) PMP-4:mCherry staining. (G) Merge of images E and F. In yellow, colocalization of
GFP:PTS-1 with PMP-4:mCherry. (H) DIC-Nomarsky images corresponding to the fluorescence images (n = 30). Scale = 5 μm in each figure except for the expanded
pictures in the squares, in which scale = 1 μm. The worms in the figures are oriented head to the left, dorsal face-up and only a portion of the central part of the body
is depicted. (I) PMP-4 and PMP-4:GFP protein levels in wild-type (WT), pmp-4(ok396) and pmp-4(ok396) animals expressing PMP-4:GFP under the control of the pmp-
4 promoter (pmp-4(ok396); Ex042 [Ppmp-4::pmp-4::gfp]) at the L4 larval stage. β-actin was used as a loading control (bottom panel) (n = 4 pools of worms by
condition). (J–K) Immunofluorescence staining of formaldehyde-fixed (J) WT and (K) pmp-4(ok396) worms incubated with polyclonal anti-PMP-4 (red) and
counterstained with DAPI (blue) at the L4 larval stage. The posterior part of the worm is depicted. I = intestine and H = hypodermis. Scale = 10 μm. (L)
Lysophosphatidylcholine fatty acid levels (LPC-20:0, LPC-22:0, LPC-24:0 and LPC-26:0) of L4 worm lysates of WT (n = 12), pmp-4(ok396)(n = 10) and daf-
22(ok693) animals (n = 6). The daf-22(ok693)mutant was used as a positive control. (M) Dinitrophenol (DNP) protein levels in WT and pmp-4(ok396) animals at the
L4 larval stage. The quantification of these blots by densitometry was performed and normalized to β-actin (n = 4 pools of worms by condition). Relative total ROS
levels (H2DCFDA) were measured by quantifying the fluorescence emission of the H2DCFDA probes in living animals in (N) WT (n = 51), (O) pmp-4(ok396)(n = 66),
(P) daf-22(ok693) (n = 40), and (Q) pmp-4(ok396) expressing PMP-4:mCherry under the control of the pmp-4 promoter (pmp-4(ok396); Ex050 [Ppmp-4::pmp-
4::mCherry]) (n = 30) L4 nematodes maintained in a liquid medium. Values are normalized to WT. Relative mitochondrial ROS levels in living animals in (R) WT
(n = 66), (S) pmp-4(ok396) (n = 88) and (T) daf-22(ok693) (n = 66) L4 nematodes quantified with MitoSox probes. Values are normalized to WT worms.
Scale = 50 μm. (U) The thrashing behaviour of WT and pmp-4(ok396) nematodes was analysed in liquid medium at L4+7 days (n = 20 animals/condition).
Representative fluorescence images of GFP-labelled GABAergic neurons showing axonal abnormalities and quantitative analysis in living worms in (V) juIs76 [Punc-
25::gfp] (n = 20), (W) pmp-4(ok396); juIs76 [Punc-25::gfp] (n = 20), and (X) pmp-4(ok396) where PMP-4:mCherry was expressed under the control of pmp-4
promoter (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex065[Ppmp-4::pmp-4::mCherry])(n = 17) at L4+7 days. Scale = 25 μm. Data represent the mean ± standard
deviation (SD). Statistical analysis was carried out with one-way ANOVA, followed by Tukey's post hoc test (*P < 0.05; **P < 0.01; ***P < 0.001).
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complexes II, III, and IV [63] on viability, revealing that pmp-4(ok396)
mutants were more sensitive to inhibitors of complexes III and IV but
not to inhibitors of complex II (Fig. 3B–E). We interpret these results as
pmp-4(ok396) animals showing impaired defences against specific mi-
tochondrial stressors.
3.4. The accumulation of lipid droplets in pmp-4(ok396) animals is
reversed by mitochondrial antioxidants
To determine which of the phenotypes due to loss of PMP-4 were
dependent on mitochondrial redox imbalance, we used two antioxidants
targeting mitochondria, Coenzyme Q10 (CoQ) and MitoQ. MitoQ is a
(caption on next page)
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Fig. 2. pmp-4(ok396)worms display lipid droplet accumulation. (A–P) At the L4 larval stage, WT and pmp-4(ok396) nematodes were fed or fasted for 24 h. (A–D)
Bright field images of the posterior part of the worm stained with Sudan Black in (A) WT + FED (n = 46), (B) WT + FASTING (n = 60), (C) pmp-4(ok396)+ FED
(n = 60), (D) pmp-4(ok396) + FASTING (n = 66), and (E) pmp-4(ok396) expressing PMP-4:mCherry under the control of pmp-4 promoter (pmp-4(ok396); Ex050
[Ppmp-4::pmp-4::mCherry])(n = 52). Lipids are evident as black droplets, labelled by a black arrow. Scale = 10 μm. Semi-quantitative analysis of the lipid droplets
with a diameter ≥ 5 μm under the indicated conditions. (F–Q) Localization of ATGL-1:GFP protein, driven by the atgl-1 promoter at L4, in (F–H) hjIs67 [Patgl-1::atgl-
1::gfp] + FED, (I–K) hjIs67 [Patgl-1::atgl-1::gfp] + FASTING, (L–N) pmp-4(ok396); hjIs67 [Patgl-1::atgl-1::gfp] + FED and (O–Q) pmp-4(ok396); hjIs67 [Patgl-1::atgl-
1::gfp]+ FASTING animals. (F) DIC-Nomarsky image and (G–H) GFP staining in WT. H is an enlarged image of G. (I) DIC-Nomarsky image and (J–K) GFP staining in
WT after 24 h of fasting. K is an enlarged image of J. (L) DIC-Nomarsky image and (M–N) GFP staining in pmp-4(ok396). N is an enlarged image of M. (O) DIC-
Nomarsky image and (P–Q) GFP staining in pmp-4(ok396); hjIs67 [Patgl-1::atgl-1::gfp] after 24 h of fasting. Q is an enlarged image of P. ATGL-1:GFP protein localized
to the surface of large lipid droplets are indicated with white arrows (n = 30 by conditions). The worms in the figures are oriented head to the left, dorsal face-up and
only a portion of the central part of the body is depicted. Scale = 5 μM. Data represent the mean ± SD. Statistical analysis was carried out with one-way (A–E) or
two-way ANOVA (F–Q), followed by Tukey's post hoc test (*P < 0.05; **P < 0.01; ***P < 0.001).
Fig. 3. Mitochondrial dysfunction in pmp-4(ok396) animals. WT and pmp-4(ok396) worms were incubated at the L4 larval stage with (A) the mitochondrial
complex I inhibitor Paraquat (PQT) (n = 51 to 54 animals by condition), the mitochondrial complex II inhibitors (B) 3-nitropropionic acid (3-NP) (n = 15 to 20
animals by condition), (C) thenoyltrifluoroacetone (TTFA) (n = 18 to 20 animals by condition), (D) the complex III inhibitor (antimycin A) (n = 20 animals by
condition) and (E) the complex IV inhibitor (sodium azide)(n = 20 animals by condition). The lethality of the worms after the treatment was evaluated as described
in the methodology. (F–Q). At L4, WT and pmp-4(ok396) nematodes were treated with CoQ (1 mg/ml) or MitoQ (5 μg/ml) for 7 days. Total ROS levels were measured
by quantifying the fluorescence emission of the H2DCFDA probes in living animals in (F) WT (n = 42), (G) pmp-4(ok396)(n = 35), (H) WT + CoQ (n = 32), (I) pmp-
4(ok396)+ CoQ (n = 30), (J) WT + MitoQ (n = 47), and (K) pmp-4(ok396)+ MitoQ (n = 32) animals at L4+7 days. Values are normalized to the untreated WT
nematodes. Scale = 50 μm. Bright field images of the posterior part of the worm stained with Sudan Black in (L) WT (n = 46), (M) pmp-4(ok396)(n = 61), (N)
WT + CoQ (n = 60), (O) pmp-4(ok396) + CoQ (n = 60), (P) WT + MitoQ (n = 30), and (Q) pmp-4(ok396) + MitoQ (n = 27) worms at L4+7 days. Lipids are
evident as black droplets, labelled by a black arrow. Scale = 10 μm. Semi-quantitative analysis of the lipid droplets with a diameter ≥ 5 μm under the indicated
conditions. Data represent the mean ± SD. Statistical analysis was carried out with Student's t-test (*P < 0.05; **P < 0.01; ***P < 0.001) for A-E. Statistical
analysis was carried out with two-way ANOVA, followed by Tukey's post hoc test (*P < 0.05; **P < 0.01; ***P < 0.001) for F-Q.
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modified form of ubiquinol attached to a lipophilic cation that enables it
to cross cell membranes and accumulate preferentially on the matrix-
facing the surface of the mitochondrial inner membrane, where it is
optimally positioned to decrease most types of mitochondrial ROS [37].
We showed that ROS levels were restored by treatment with both com-
pounds, although much lower doses of MitoQ were necessary (200-fold
less compared to CoQ) (Fig. 3F–K), underscoring the mitochondrial
origin of the redox imbalance in the absence of PMP-4. Next, we in-
cubated pmp-4(ok396) with CoQ and MitoQ to investigate whether the
observed increase in LDs involved a mitochondrial redox-dependent
mechanism. Remarkably, the enlargement of LDs could be normalized
upon treatment with these two mitochondrial antioxidants (Fig. 3L–Q).
(caption on next page)
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3.5. Axonal degeneration in pmp-4(ok396) mutants is caused by
mitochondrial ROS
Next, we examined the effect of CoQ and MitoQ on axonal defects
and locomotion disabilities in the pmp-4(ok396) worms. Thrashing
abnormalities were restored by CoQ, but more efficiently by the mi-
tochondrial-targeted MitoQ, at L4 (Supplementary Fig. S2E) and L4+7
days (Fig. 4A). This effect was correlated with an improvement of ax-
onal damage with CoQ and MitoQ at L4+7 days (Fig. 4B–G).
We further investigated the role of mitochondrial ROS production in
the maintenance of locomotion and axonal health. To address a cause-
effect relationship, we evaluated the thrashing behaviour and axonal
morphology in N2 and pmp-4(ok396) worms exposed to PQT at a
200 μM sublethal dose at L4+7 days (Fig. 4H-N). PQT treatment re-
duced the locomotion fitness and increased axonal damage in both N2
and pmp-4(ok396) worms, with an exacerbated effect in pmp-4(ok396)
worms (Fig. 4H-L). Importantly, MitoQ normalized these abnormalities
(Fig. 4H-N).
To provide orthogonal evidence for the axonal defects caused by
damage to the mitochondrial oxidative phosphorylation (OXPHOS)
system, we performed RNAi knockdown of the mitochondrial gene nuo-
1, encoding the NDUFB4/B15 subunit of complex I required for
OXPHOS, in WT worms [64]. We found that nuo-1 RNAi worms re-
capitulated the axonal defects present in the GABAergic neurons of
pmp-4(ok396) and PQT-treated worms at L4+7 days (Supplementary
Figs. S2F–G). Altogether, these results indicated that mitochondrial
ROS generated by the loss of PMP-4 are detrimental for axonal in-
tegrity, causing defects in locomotion.
3.6. PMP-4 expression in the hypodermis rescues locomotor disability and
axonal degeneration through cell non-autonomous mechanisms
We then attempted to restore PMP-4 in the tissues where its en-
dogenous expression was higher by expressing PMP-4:mCherry in the
hypodermis (Ex177 [Pdpy-7::pmp-4::mCherry]) or in the intestine
(Ex151 [Pges-1::pmp-4::mCherry]), using the strain previously used for
characterizing the axonal defects, pmp-4(ok396); juIs76 [Punc-25::gfp],
as background (Fig. 5A–E). We also expressed PMP-4:mCherry in GFP-
labelled GABAergic cells (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex191
[Punc-25::pmp-4::mCherry]), as additional confirmation (Fig. 5A and F).
Locomotion defects were only rescued when PMP-4:mCherry was ex-
pressed in the hypodermis but not in the intestine or in GABAergic
neurons (Fig. 5A, movies S3-S7). Axonal damage was also rescued by
restoring the expression of PMP-4:mCherry in hypodermal cells
(Fig. 5B–D) but not in intestinal cells (Fig. 5B–C, 5E) or in GABAergic
cells (Fig. 5B–C, 5F). Collectively, these results provide evidence that
restoring the function of PMP-4 in the hypodermis is necessary and
sufficient to maintain axonal integrity and locomotion in a cell non-
autonomous manner.
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.freeradbiomed.2020.01.177
4. Discussion
This work provides a novel animal model for a dreadful neurome-
tabolic disorder, which, beyond the practicalities of cost-beneficial in
vivo drug screening, delivers fundamental insights for an improved
understanding of its molecular pathogenesis. pmp-4 deficient worms
recapitulate the main hallmarks observed in human AMN patients and
Abcd1- mice, i.e., the accumulation of VLCFAs, the mitochondrial redox
imbalance, and most importantly, the axonal degeneration and asso-
ciated locomotor dysfunction [5,18,65], indicating that the mechan-
isms leading to disease upon PMP-4 dysfunction are evolutionarily
conserved. We have previously shown that oxidative damage is a direct
consequence of fatty acid excess and appears well in advance of the
onset of symptoms [47,50] and that the combination of antioxidants N-
acetylcysteine, lipoic acid and vitamin E could halt axonal degeneration
in the mouse model [49]. Our working hypothesis is based on the in-
terference of intracellular excess VLCFAs or membrane lipidic compo-
nents containing lateral chains of VLCFAs with OXPHOS assembly or
interaction, which leads to the generation of excess ROS and diminish
ATP at this site [66]. The study of PMP-4 function in C. elegans expands
these findings and provides precise evidence of enhanced mitochondrial
vulnerability, since inhibitors of complexes I, III and IV dramatically
increase pmp-4(ok396) lethality. We also show a direct causative role
for mitochondrial redox dysfunction in axonal demise, since the selec-
tive mitochondrial antioxidant MitoQ prevented axonal degeneration.
Altogether these results strengthen the rationale for using antioxidants
targeting mitochondria to modify the progression of this peroxisomal
disease, such as MitoQ, which has been used safely in phase II trials for
Parkinson's [67] and has shown clinical efficacy in vascular function in
healthy elderly individuals [68].
It is worth noting that we did not observe redox imbalance in the
peroxisomal thiolase, beta-oxidation defective daf-22(ok693) mutant.
This is also the case when the first limiting enzyme of peroxisomal beta-
oxidation, the acetyl-CoA oxidase, is silenced in HepG2 cells [69]. A
plausible explanation may be that, in these mutants, VLCFA enter
peroxisomes and presumably remain inside the organelles, thus pre-
serving mitochondria membrane fluidity.
Regarding the biochemical defect presented by the pmp-4(ok396)
mutants, we observed a modest 1.25-fold increase in LPC-C26:0 levels
compared to WT. These differences are lower than the three to six fold
increases found in plasma and tissues of patients and mouse models
[26,70], but consistent with the C26:0 levels detected in the zebrafish
model where abcd1 gene is deleted [71]. The lower levels of C26:0 in
both animal models compared to humans may owe to the fact that
C26:0 have been quantified in whole fish or worms. In contrast, the
excess of C26:0 levels is variable in the mouse depending of the tissues,
ranging from 1.5-fold in the liver to 6-fold in the sciatic nerve [16,72].
The finding of expanded LD compartment in pmp-4(ok396) mutants
is intriguing. Similar increases in LD in glial cells in drosophila has been
described as a result of oxidative stress-either originated under hypoxic
conditions or due to excess free radicals [73]. The authors attributed to
the increased LD a protective effect through the sequestration of
Fig. 4. Mitochondrial-targeted antioxidant rescue axonal abnormalities and locomotor dysfunction at old stages of development. (A–G) At the L4 larval
stages, WT and pmp-4(ok396) nematodes were treated with CoQ (1 mg/ml) or MitoQ (5 μg/ml) for 7 days. (A) The thrashing behaviour was carried out in WT and
pmp-4(ok396) nematodes upon CoQ or MitoQ at L4+7 days (n = 15 to 27 animals by condition). Representative fluorescence images showing axonal abnormalities
and quantitative analysis at the indicated genotypes upon CoQ or MitoQ at L4+7 days in (B) juIs76 [Punc-25::gfp] (n = 20), (C) pmp-4(ok396); juIs76 [Punc-25::gfp]
(n = 20), (D) juIs76 [Punc-25::gfp]+ CoQ (n = 18), (E) pmp-4(ok396); juIs76 [Punc-25::gfp]+ CoQ (n = 15), (F) juIs76 [Punc-25::gfp]+ MitoQ (n = 26) and (G)
pmp-4(ok396; juIs76 [Punc-25::gfp])+ MitoQ (n = 27). White asterisks indicate axonal abnormalities. All worms are oriented with the anterior end left and ventral
side down. Scale = 25 μm. (H–N) At the L4 larval stage, juIs76 [Punc-25::gfp]and pmp-4(ok396); juIs76 [Punc-25::gfp] nematodes were treated with paraquat (PQT)
(0.2 mM) and/or MitoQ (5 μg/ml) for 7 days. (H) The thrashing behaviour was analysed at stage L4+7 days in WT and pmp-4(ok396) nematodes upon PQT and/or
MitoQ (n = 20 to 31 animals by condition). Representative fluorescence images showing axonal abnormalities and quantitative analysis at stage L4+7 days in (I)
juIs76 [Punc-25::gfp]) (n = 29), (J) pmp-4(ok396); juIs76 [Punc-25::gfp] (n = 31), (K) juIs76 [Punc-25::gfp] + PQT(n = 25), (L) pmp-4(ok396); juIs76 [Punc-
25::gfp]+ PQT (n = 20), (M) juIs76 [Punc-25::gfp]+ PQT + MitoQ (n = 21), (N) pmp-4(ok396; juIs76 [Punc-25::gfp]+ PQT + MitoQ (n = 28). Scale = 25 μm. All
worms are oriented with the anterior end left and ventral side down. Data represent the mean ± standard deviation (SD). Statistical analysis was carried out with
two-way ANOVA, followed by Tukey's post hoc test (*P < 0.05; **P < 0.01; ***P < 0.001) for A-N.
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vulnerable membrane fatty acids away from free radicals, thus avoiding
a devil circle of lipid peroxidation [73]. On the other hand, an emerging
role for LDs in the pathogenesis of neurodegenerative disease is evi-
denced by the identification of several key regulators as causative genes
of corticospinal axonal demise, such as Spastin, Reep1, or Atlastin-1
[74,75]. Reports on the increase or enlargement of LDs in peroxisomal
disorders are scarce but include a mouse mutant of the peroxisomal
biogenesis factor PEX5, causing Zellweger syndrome [76]. C. elegans
responds to starvation by activating a number of genes involved in lipid
metabolism, including the mitochondrial and peroxisomal β-oxidation
genes, as these organelles cooperate in LD degradation [39,77]. During
fasting, when the main fuel arrives from fatty acid stores, the loss of
PMP-4 may impede their degradation in peroxisomes. We hypothesize
that healthy mitochondria may compensate for the loss of peroxisomal
function for degrading LD-derived fatty acids. This compensation may
explain why treatment with antioxidants, which may exert protective
effects on mitochondrial function and boost β-oxidation [78], nor-
malizes the expanded LD compartment increasing the degradation of
the fatty acids contained inside. This relationship appears reciprocal, as
the production of mitochondrial ROS in neurons activates pathways
inducing LD formation in glial cells, in a cell non-autonomous manner,
in Drosophila and mouse models of OXPHOS impairment [79]. More-
over, increased LDs have been shown to be detrimental under condi-
tions of marked mitochondrial oxidative stress, causing the enhance-
ment of lipid peroxidation and neurodegeneration in Drosophila and
mouse models overexpressing the fatty acid transporter FATP [80].
Based on the strong body of evidence implicating mitochondrial dys-
function and particularly the OXPHOS system in the pathogenetic
cascade in X-ALD [14,48,50,51], we posit that the negative impacts of
mitochondrial redox imbalance may be exacerbated by LD accumula-
tion, leading to axonal degeneration. Elucidation of the precise me-
chanism orchestrating the regulation of LD formation by redox signal-
ling may bear therapeutic potential and impact for neurodegenerative
conditions in which mitochondria and LD dyshomeostasis converge.
The ectopic expression of PMP-4:mCherry in the hypodermis of pmp-
4(ok396) nematodes was sufficient to halt axonal degeneration, while
no effect was observed when PMP-4:mCherry was expressed in the in-
testine or in neurons. This evidence indicates a fundamental metabolic
role for the peroxisome compartment in the hypodermis that is neces-
sary to maintain axonal integrity via a cell non-autonomous me-
chanism, which is supported by previous data in mice. The model shows
that oligodendrocyte-specific ablation of functional peroxisomes
through inactivation of the Pex5 gene, is sufficient to cause severe ax-
onal degeneration [81].
Indeed, C. elegans hypodermal cells participate in guiding neuronal
migration and share characteristics with vertebrate glial cells [82],
enveloping neuronal cell bodies and their processes and supporting
neuronal function and architecture [83]. During embryogenesis, the
hypodermis is implicated in neuronal migration [84] and later in de-
velopment, axons grow completely embedded into the hypodermis
[83,84]. Thus, it is likely that the strict physical contact may facilitate
Fig. 5. Specific PMP-4 expression in the hypodermis is essential to main-
tain axonal integrity and locomotion. (A) Locomotion behaviour expressed
as thrashes per minute at L4+7 days in juIs76 [Punc-25::gfp], pmp-4(ok396);
juIs76 [Punc-25::gfp] and pmp-4(ok396; juIs76 [Punc-25::gfp]) animals where
PMP-4:mCherry is expressed in hypodermis (pmp-4(ok396); juIs76 [Punc-
25::gfp]; Ex177 [Pdpy-7::pmp-4::mCherry]), in intestine (pmp-4(ok396); juIs76
[Punc-25::gfp]; Ex151 [Pges-1::pmp-4::mCherry]) or in neurons (pmp-4(ok396);
juIs76 [Punc-25::gfp]; Ex191 [Punc-25::pmp-4::mCherry]) (n = 19 to 23 animals
by condition). Representative confocal pictures showing axonal damage and
quantitative analysis in (B) juIs76 [Punc-25::gfp] (n = 22), (C) pmp-4(ok396);
juIs76 [Punc-25::gfp] animals (n = 19), pmp-4(ok396) animals where PMP-
4:mCherry is expressed in (D) hypodermis (pmp-4(ok396); juIs76 [Punc-25::gfp];
Ex177 [Pdpy-7::pmp-4::mCherry]) (n = 23), (E) intestine (pmp-4(ok396); juIs76
[Punc-25::gfp]; Ex151 [Pges-1::pmp-4::mCherry]) (n = 22) or (F) neurons (pmp-
4(ok396); juIs76 [Punc-25::gfp]; Ex191 [Punc-25::pmp-4::mCherry]) (n = 19).
The red colour in all pictures corresponds to the strong expression in the
pharynx of the co-injection marker Pmyo-2::mCherry. White asterisks label the
axonal abnormalities. Worms are oriented head to the left and dorsal face-up.
Scale = 25 μm. Data represent the mean ± standard deviation (SD). Statistical
analysis was carried out with two-way ANOVA, followed by Tukey's post hoc
test (*P < 0.05; **P < 0.01; ***P < 0.001).
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the passage of signalling or nurturing metabolites, such as essential li-
pids, from peroxisomes in the hypodermis towards axons. For instance,
the neuroprotective DHA (C22:6ω3) is synthetized in peroxisomes by
the β-oxidation of C24:6ω3, which is imported into peroxisomes by
ABCD1 and ABCD2 transporters, the mouse orthologues of PMP-4 [39].
A model of laser-induced axotomy provides evidence of a cell non-au-
tonomous mechanism implicating the hypodermis in the maintenance
of axonal integrity [85]. Thus, we posit that hypodermis may play a key
supporting role in the protection and maintenance of neurons and axons
in nematodes, similar to myelin in mammals, underscoring the im-
portance of this tissue in models of axonal or neuronal degeneration in
C. elegans.
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